Tracon Pharmaceuticals Obtains $14,000,000 New Financing Round

  • Feed Type
  • Date
    4/1/2011
  • Company Name
    Tracon Pharmaceuticals
  • Mailing Address
    8910 University Center Dr. San Diego, CA 92122
  • Company Description
    TRACON Pharmaceuticals, Inc. is a fast growing biotechnology company developing next-generation targeted therapies for cancer and related diseases. We are addressing unmet needs in this arena with product candidates that focus on cellular targets specifically implicated in cancer growth and angiogenesis.
  • Website
    http://www.traconpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $14,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from the financing will advance the development of the antibody TRC105, an inhibitor of angiogenesis that is being developed in multiple Phase 1b and Phase 2 indications, that are supported by the National Cancer Institute, including ongoing trials in prostate, bladder and liver cancer.
  • M&A Terms
  • Venture Investor
    Jafco Ventures
  • Venture Investor
    Nextech Invest
  • Venture Investor
    Arcus Ventures
  • Venture Investor
    Brookline Venture Partners
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.